{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T23:10:40Z","timestamp":1779923440730,"version":"3.53.1"},"reference-count":26,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2016,3,24]],"date-time":"2016-03-24T00:00:00Z","timestamp":1458777600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Liver International"],"published-print":{"date-parts":[[2016,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background &amp; Aims<\/jats:title><jats:p>Role of non\u2010adherence upon virological success with newer oral regimens is unknown. We sought to determine the impact of treatment adherence upon virological outcomes in hepatitis C virus (<jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content>) infected persons on sofosbuvir (<jats:styled-content style=\"fixed-case\">SOF<\/jats:styled-content>)\u2010based regimens, using pharmacy prescription data as a measure of adherence.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We analysed <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content> infected persons in Electronically Retrieved Cohort of <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content> Infected Veterans, who were initiated on SOF\u2010based regimens, excluding those with human immunodeficiency virus, positive hepatitis\u2010B surface antigen, hepatocellular carcinoma and missing <jats:styled-content style=\"fixed-case\">HCV RNA<\/jats:styled-content>.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The final dataset included following regimens: <jats:styled-content style=\"fixed-case\">SOF<\/jats:styled-content>+simeprevir (<jats:styled-content style=\"fixed-case\">SIM<\/jats:styled-content>) (<jats:italic>n<\/jats:italic> = 1050), <jats:styled-content style=\"fixed-case\">SOF<\/jats:styled-content>+ledipasvir (<jats:styled-content style=\"fixed-case\">LDV<\/jats:styled-content>) (<jats:italic>n<\/jats:italic> = 974), <jats:styled-content style=\"fixed-case\">SOF<\/jats:styled-content>+ribavirin (<jats:styled-content style=\"fixed-case\">RBV<\/jats:styled-content>) (<jats:italic>n<\/jats:italic> = 663, genotype 2 or 3), and SOF+pegylated interferon (<jats:styled-content style=\"fixed-case\">PEG<\/jats:styled-content>)+<jats:styled-content style=\"fixed-case\">RBV<\/jats:styled-content> (<jats:italic>n<\/jats:italic> = 519, genotype 1 or 4). Those treated with a SOF\u2010based regimen were older and more likely to have cirrhosis, diabetes, chronic kidney disease, higher <jats:styled-content style=\"fixed-case\">HCV RNA<\/jats:styled-content> levels, higher body mass index, compared with 1652 controls receiving a boceprevir\u2010based (<jats:styled-content style=\"fixed-case\">BOC<\/jats:styled-content>) regimen. Sustained virological response (<jats:styled-content style=\"fixed-case\">SVR<\/jats:styled-content>12) rates for the <jats:styled-content style=\"fixed-case\">SOF<\/jats:styled-content>+<jats:styled-content style=\"fixed-case\">SIM<\/jats:styled-content> and <jats:styled-content style=\"fixed-case\">SOF<\/jats:styled-content>+<jats:styled-content style=\"fixed-case\">LDV<\/jats:styled-content> groups did not decline significantly even when as low as 50% of the full course was prescribed (except <jats:styled-content style=\"fixed-case\">SOF<\/jats:styled-content>+<jats:styled-content style=\"fixed-case\">LDV<\/jats:styled-content>, 90\u201399% prescriptions had <jats:styled-content style=\"fixed-case\">SVR<\/jats:styled-content>12 of 84.6%; <jats:italic>n<\/jats:italic> = 13). <jats:styled-content style=\"fixed-case\">SOF<\/jats:styled-content>+<jats:styled-content style=\"fixed-case\">RBV<\/jats:styled-content> for genotype 2\/3 who received 50\u201380% of the prescriptions, 23\/34 (67.6%) achieved <jats:styled-content style=\"fixed-case\">SVR<\/jats:styled-content>12. For persons with genotype 1\/4 infection treated with <jats:styled-content style=\"fixed-case\">SOF<\/jats:styled-content>+<jats:styled-content style=\"fixed-case\">PEG<\/jats:styled-content>+<jats:styled-content style=\"fixed-case\">RBV<\/jats:styled-content>, no declines in <jats:styled-content style=\"fixed-case\">SVR<\/jats:styled-content>12 were seen with lower rates of prescriptions (40\/43, or 93% <jats:styled-content style=\"fixed-case\">SVR<\/jats:styled-content>12 rate).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Sofosbuvir\u2010based treatment regimens are highly effective in achieving <jats:styled-content style=\"fixed-case\">SVR<\/jats:styled-content>12. This efficacy is not significantly affected when treated persons receive less than a full prescribed course of treatment.<\/jats:p><\/jats:sec>","DOI":"10.1111\/liv.13103","type":"journal-article","created":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T10:19:59Z","timestamp":1456827599000},"page":"1275-1283","source":"Crossref","is-referenced-by-count":23,"title":["Treatment adherence and virological response rates in hepatitis C virus infected persons treated with sofosbuvir\u2010based regimens: results from <scp>ERCHIVES<\/scp>"],"prefix":"10.1111","volume":"36","author":[{"given":"Adeel A.","family":"Butt","sequence":"first","affiliation":[{"name":"VA Pittsburgh Healthcare System Pittsburgh PA USA"},{"name":"Hamad Healthcare Quality Institute and Hamad Medical Corporation Doha Qatar"},{"name":"Weill Cornell Medical College Doha Qatar"},{"name":"Weill Cornell Medical College New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Yan","sequence":"additional","affiliation":[{"name":"VA Pittsburgh Healthcare System Pittsburgh PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Obaid S.","family":"Shaikh","sequence":"additional","affiliation":[{"name":"VA Pittsburgh Healthcare System Pittsburgh PA USA"},{"name":"University of Pittsburgh School of Medicine Pittsburgh PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond T.","family":"Chung","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital Boston MA USA"},{"name":"Harvard Medical School Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth E.","family":"Sherman","sequence":"additional","affiliation":[{"name":"University of Cincinnati College of Medicine\/UC Health Cincinnati OH USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the ERCHIVES study","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,3,24]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12546"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir774"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(13)70033-1"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60247-0"},{"key":"e_1_2_8_6_1","first-page":"10","article-title":"Simeprevir with peginterferon\/ribavirin for treatment\u2010naive hepatitis C genotype 1 patients in Japan: CONCERTO\u20101, a phase III trial","volume":"14","author":"Hayashi N","year":"2014","journal-title":"J Hepatol"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-014-0949-8"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-011-9278-7"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2010.01287.x"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-015-3621-0"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12375"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.12729"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2015.21.2.153"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2011.03608.x"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1881"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1L496"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2007.00885.x"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1086\/599371"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23000"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2009.02156.x"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2010.09.023"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12107"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2013.01.023"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27835"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2014.6502"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1310\/hct1001-25"},{"key":"e_1_2_8_27_1","volume-title":"Haemoglobin Concentrations for the Diagnosis of Anaemia and Assessment of Severity. Vitamin and Mineral Nutrition Information System","author":"World Health Organization","year":"2011"}],"container-title":["Liver International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fliv.13103","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fliv.13103","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/liv.13103","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T17:33:40Z","timestamp":1695490420000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/liv.13103"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,24]]},"references-count":26,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["10.1111\/liv.13103"],"URL":"https:\/\/doi.org\/10.1111\/liv.13103","archive":["Portico"],"relation":{},"ISSN":["1478-3223","1478-3231"],"issn-type":[{"value":"1478-3223","type":"print"},{"value":"1478-3231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,24]]}}}